Gerresheimer cuts guidance for 2025 citing weak demand

Gerresheimer (GXIG.DE) has lowered its 2025 revenue growth forecast to 1-2% from a previous 3-5% due to weak demand in the cosmetics sector and for liquid medication containment solutions; the adjusted EBITDA margin forecast was also reduced to 20% from 22%. The company reduced its 2024 dividend to €0.04 per share from the initially proposed €1.25 to preserve financial flexibility. Following the announcement, Gerresheimer shares fell by as much as 11% and were trading down 10.02% at 1000 GMT.

Analysis

Gerresheimer (GXIG.DE) has materially lowered its financial guidance for 2025, signaling significant operational headwinds. The company now anticipates revenue growth of only 1-2%, a marked reduction from the previous 3-5% forecast, even inclusive of contributions from Bormioli Pharma. This revision is directly attributed to continued weak demand in the cosmetics sector and a notable decline in demand for its containment solutions for liquid medications. Alongside the top-line pressure, Gerresheimer has also reduced its expected adjusted EBITDA margin for 2025 to 20%, down from 22%. In a move to preserve financial flexibility amidst these challenges, the 2024 dividend has been drastically cut to €0.04 per share from the €1.25 proposed in February. The market's reaction was immediate and severe, with shares plummeting as much as 11% and trading 10.02% lower, consistent with the reported strongly negative sentiment and pessimistic tone. This guidance cut underscores a deteriorating outlook for the company's core businesses and profitability in the near term.

Key Decisions for Investors

• Investors should rigorously re-evaluate their investment thesis and valuation models for Gerresheimer to incorporate the substantially reduced revenue growth and profitability outlook for 2025.
• Closely monitor demand trends in Gerresheimer's key end-markets, specifically the cosmetics sector and liquid medication containment solutions, for any signs of stabilization or further weakening.
• Given the significant dividend cut to €0.04, income-focused investors should reassess the stock's attractiveness, while all investors should consider the implications for the company's capital allocation strategy and perceived financial health.